Metafolin

PreclinicalSmall molecule

UUniversity of California, San Diego

Metafolin is one of 7 small molecule programs targeting Angelman syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Angelman SyndromeActive, not recruiting

Angelman SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Angelman Syndrome

#DrugCompanyPhaseTrials

Lodosyn

GTX-102

4 3

Obudanersen

Ionis Pharmaceuticals

Phase 3

2 4

ION582

Ionis Pharmaceuticals

Phase 3

2 5

Rugonersen

OOak Hill Bio Ltd

Phase 3

2 6

Cystadane

RRECORDATI GROUP

Preclinical

1 7

Metafolin

UUniversity of California, San Diego

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Angelman syndrome1 trial

Dietary Supplements for the Treatment of Angelman Syndrome

Completed·UUniversity of California, San Diego·N/A·NCT00348933·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Metafolin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metafolin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metafolin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Diego company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of California, San Diego

Metafolin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Angelman syndrome1 trial

References

Drug Info

Quick Facts

Related News